Retisert: Phase III

An intent-to-treat analysis of 12-month follow-up data from a Phase III trial in 80 patients showed that 48.8% of patients that received the 0.5 mg Retisert insert had a

Read the full 298 word article

How to gain access

Continue reading with a
two-week free trial.